Trapelo™ assures that each lab order is precisely determined by the characteristics of each patient’s tumor, and is supported by up-to-date clinical evidence, eliminating the need for prior authorization for molecular medicine. This reduces unnecessary costs while expediting and streamlining the process.
Comprehensive: Effective for all solid tumors
Connected: Integrated with providers and labs
Convenient: Accessible from within your own portal
PRECISION CARE MANAGEMENT FOR PAYORS
“For the majority of payers, cost has risen to become the most important factor influencing biomarker coverage, followed closely by clinical validity and utility.”
– The Precision Oncology Annual Trend Report, 2016